TP53 and cancer: Moreover, combined loss of ATR and TRP53 revealed the striking phenotypes of synthetic lethality, a finding that was crucial for the development of current approaches targeting ATR in cancer therapies (Lecona and Fernandez-Capetillo, 2018; Murga et al., 2009; Ruzankina et al., 2009).